Hence, the identification of the patient population who may benefit most from CD25 Mab requires further characterization of the AML blast and microenvironment in a larger sample size, analyzing emerging clinical data from HMA-VEN trials, and testing ex vivo cell killing or the impact on effector T cell function on more treatment naïve and relapsed/refractory AML samples. Here, IL2RA is linked to acute myeloid leukemia.